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Serial MRI to determine the eﬀ ect of dexamethasone on the 
cerebral pathology of tuberculous meningitis: an 
observational study
Guy E Thwaites, Jeremy Macmullen-Price, Tran Thi Hong Chau, Pham Phuong Mai, Nguyen Thi Dung, Cameron P Simmons,  Nicholas J White, 
Tran Tinh Hien, David Summers, Jeremy J Farrar
Summary
Background Adjunctive dexamethasone increases survival from tuberculous meningitis, but the underlying 
mechanism is unclear. We aimed to determine the eﬀ ect of dexamethasone on cerebral MRI changes and their 
association with intracerebral inﬂ ammatory responses and clinical outcome in adults treated for tuberculous 
meningitis.
Methods Cerebral MRI was undertaken, when possible, at diagnosis and after 60 days and 270 days of treatment in 
adults with tuberculous meningitis admitted to two hospitals in Vietnam. Patients were randomly assigned either 
dexamethasone (n=24) or placebo (n=19) and received 9 months of treatment with standard ﬁ rst-line antituberculosis 
drugs. We assessed associations between MRI ﬁ ndings, treatment allocation, and resolution of fever, coma, 
cerebrospinal ﬂ uid inﬂ ammation, and neurological outcome. 
Findings 83 scans were done for 43 patients: 19 given placebo, 24 given dexamethasone. Basal meningeal enhancement 
(82%) and hydrocephalus (77%) were the most common presenting ﬁ ndings. Fewer patients had hydrocephalus after 
60 days of treatment with dexamethasone than after placebo treatment (p=0·217). Tuberculomas developed in 74% of 
patients during treatment and in equal proportions in the treatment groups; they were associated with long-term 
fever, but not relapse or poor clinical outcome. The basal ganglia were the most common site of infarction; the 
proportion with infarction after 60 days was halved in the dexamethasone group (27% vs 58%, p=0·130).
Interpretation Dexamethasone may aﬀ ect outcome from tuberculous meningitis by reducing hydrocephalus and 
preventing infarction. The eﬀ ect may have been under-estimated because the most severe patients could not be 
scanned.  
Introduction
More than half of patients with tuberculous meningitis 
are disabled by or die from the disease, but the underlying 
mechanisms responsible for the poor outcome are not 
well understood.1 The disease is characterised by a 
necrotising granulomatous inﬂ ammatory response, 
which predominantly aﬀ ects the structures of the 
midbrain and the hindbrain.2 Inﬂ ammatory exudate can 
obstruct the ﬂ ow of cerebrospinal ﬂ uid (CSF) and cause 
hydrocephalus. Adhesions can compromise cranial 
nerves and an obliterative vasculitis of both large and 
small vessels can result in infarction and stroke 
syndromes. Granulomas can coalesce to form 
tuberculomas, causing diverse clinical problems 
depending on their size and location.
There are few interventions available to prevent or treat 
these life-threatening complications. We undertook a 
controlled trial3 of dexamethasone in 545 Vietnamese 
adults with tuberculous meningitis. The ﬁ ndings showed 
that dexamethasone improved survival but did not 
prevent severe disability. To determine how 
dexamethasone exerted its eﬀ ect we examined the 
kinetics of the inﬂ ammatory response in peripheral and 
CSF specimens from 87 adults recruited to the trial. 
Dexamethasone did not seem to improve outcome by 
attenuating immunological mediators of inﬂ ammation 
in the subarachnoid space or by suppressing peripheral 
T-cell response to mycobacterial antigens.4 These ﬁ ndings 
challenged previously held theories of corticosteroid 
action in this disease, although the study was limited to 
sampling blood and CSF at infrequent timepoints and 
these data were not linked to the presence or development 
of inﬂ ammatory exudates, hydrocephalus, infarction, 
and tuberculomas. 
The eﬀ ect of dexamethasone on these common 
complications of tuberculous meningitis has not been 
well studied. Schoeman and colleagues5 did a randomised 
controlled trial of adjunctive corticosteroids in South 
African children with the disease and assessed the eﬀ ect 
of these drugs on direct measurements of intracranial 
pressure, serial cerebral CT, and clinical outcome. The 
trial showed improved survival in the corticosteroid 
group, but no diﬀ erence in intracranial pressure, 
ventricular size, or extent of infarction between those 
treated with or without corticosteroids. The authors 
postulated that corticosteroids exerted a beneﬁ cial eﬀ ect 
by reducing basal meningeal inﬂ ammation and 
associated brain-stem encephalopathy, but suggested 
that the drugs did not modify infarct-causing peri-
arteritis.
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To further examine the mechanism of action of 
dexamethasone in the treatment of tuberculous 
meningitis we undertook serial MRI on a cohort of adults 
with the disease recruited consecutively to our controlled 
trial of dexamethasone. These patients also had serial 
measurements of CSF inﬂ ammatory mediators. Our aim 
was to describe the cerebral MRI changes seen in adults 
treated for tuberculous meningitis and to determine the 
eﬀ ect of dexamethasone on those changes and their 
association with intracerebral inﬂ ammatory responses 
and clinical outcome.
Methods
Participants
A randomised, double-blind, placebo-controlled trial of 
adjunctive dexamethasone for the treatment of 
tuberculous meningitis was undertaken in 545 adults 
between April, 2001, and April, 2003, according to 
methods described previously.3 Two centres in Ho Chi 
Minh City, Vietnam, recruited patients to the study: Pham 
Ngoc Thach Hospital for tuberculosis and lung disease 
(n=452) and the Hospital for Tropical Diseases (n=93). 
Randomisation was stratiﬁ ed according to hospital of 
entry and disease severity grade. The eﬀ ects of 
dexamethasone on intracerebral immune response and 
cerebral MRI appearances were studied in all adults 
recruited at the Hospital for Tropical Diseases from 
January, 2002, onwards (n=50). Adults (>14 years) with 
deﬁ nite, probable, or possible tuberculous meningitis 
were eligible to enter the trial, as deﬁ ned previously.3
The ethical and scientiﬁ c committees of the hospitals, 
the health services of Ho Chi Minh City, and the Oxford 
Clinical Research Ethics Committee approved the study 
protocols. Written informed consent to participate in the 
study was obtained from all patients or their relatives.
Procedures
All patients received standard ﬁ rst-line antituberculosis 
drugs for 9 months.3 Additionally, patients were 
randomly allocated to start dexamethasone sodium 
phosphate or placebo as soon as possible after the start 
of antituberculosis treatment. Those with a Glasgow 
coma score less than 15 or focal neurological deﬁ cit at 
the start of treatment received intravenous drugs for 
4 weeks (0·4 mg/kg per day for week 1, 0·3 mg/kg per 
day week 2, 0·2 mg/kg per day week 3, 0·1 mg/kg per 
day week 4) followed by 4 mg total of oral drug, reduced 
each week by 1 mg until zero was reached. Those without 
coma or neurological signs received intravenous drug 
for 2 weeks (0·2 mg/kg per day week 1, 0·1 mg/kg per 
day week 2), followed by the same oral reducing course 
described above. None of the patients received 
antiretroviral drugs or any second-line antituberculosis 
drugs and ventricular-peritoneal shunting was not 
oﬀ ered to any of the patients.
Serial paired CSF and peripheral blood samples were 
obtained from all patients before and after starting the 
study drug (days 3, 7, 30, 60, and 270) as part of normal 
clinical care. CSF concentrations of leucocytes, lactate, 
glucose, and protein were measured by standard methods. 
All other measurements were done on aliquots of CSF 
supernatant frozen at –70ºC. All patients were tested for 
antibodies to HIV-1 and HIV-2, although antiretroviral 
drugs were not available at the time of the study.
Cerebral MRI was undertaken on a 1·5T MR system 
(General Electric, USA) at the start of treatment and as 
close as possible to 60 days and 270 days thereafter. The 
scanner was located outside the hospital and patients 
could only be scanned if medically stable and ﬁ t for 
transfer to this facility. The reasons for missed scans 
were not recorded. The principal MRI sequences included 
T1 and T2 axial and post-contrast axial T1 cranial imaging. 
The scans were reviewed by two experienced 
neuroradiologists unaware of treatment allocation and 
patient outcome.
Systematic assessment of the imaging studies was 
undertaken with discrepancies between reviewers agreed 
by consensus. The features recorded were the abnormal 
enhancement of the leptomeninges (basal, sylvian 
ﬁ ssure, convexity and ependymal), the presence, number, 
and distribution of tuberculomas (deﬁ ned as a focal 
punctate area of parenchymal, ependymal, or 
leptomeningeal enhancement), hydrocephalus (pan-
ventricular or localised, communicating or non-
Placebo 
(n=19)
Dexamethasone 
(n=24) 
Total 
(n=43) 
Male sex 12 (63%) 15 (63%) 27 (63%)
Age (years) 32 (18–66) 24 (15–59) 31 (15–66)
Weight (kg) 49 (33–61) 47 (43–73) 47 (33–73)
HIV infection 1 (5%) 0 1 (2%)
Duration of symptoms (days) 17 (5–60) 18 (5–45) 17 (5–60)
Tuberculous meningitis diagnosis
Deﬁ nite 12 (63%) 15 (63%) 27 (63%)
Probable 3 (16%) 4 (17%) 7 (16%)
Possible 4 (21%) 5 (21%) 9 (21%)
BMRC grade
I 6 (32%) 8 (33%) 14 (33%)
II 11 (58%) 8 (33%) 19 (44%)
III 2 (11%) 8 (33%) 10 (23%)
Temperature (ºC) 38·6 (37·0–40·0) 39·0 (37·0–41·0) 38·9 (37·0–41·0)
Cerebrospinal ﬂ uid
Opening pressure (cm H2O) 18 (5–40); [n=18] 25 (7–40); [n=23] 22 (5–40); [n=41]
White cell count (× 106/mL) 275 (51–1120); [n=18] 240 (10–1880) 260 (10–1880); [n=42]
% neutrophil 29 (2–80); [n=18] 32 (2–90) 30 (2–90); [n=42]
% lymphocytes 71 (20–98); [n=18] 68 (10–98) 70 (10–98); [n=42]
Total protein (mg/L) 1980 (500–5710) 2000 (840–7200) 2000 (500–7200)
Lactate (mmol/L) 6·1 (2·3–13·5); [n=16] 5·9 (2·8–15·1); [n=20] 6·2 (2·3–15·1); [n=36]
CSF:plasma glucose 0·28 (0·06–0·72) 0·25 (0·04–0·45) 0·25 (0·04–0·72)
Data are number (%) or median (range). Number and denominator given only when there are missing values.
Table 1: Baseline characteristics of patients with one or more MRI scans
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communicating), and the presence, number, and 
distribution of infarcts. Hydrocephalus was deﬁ ned as 
the presence of dilated temporal horns, or dilated lateral 
and third ventricles with or without a dilated fourth 
ventricle (the fourth ventricle is usually the last ventricle 
to dilate). Communicating hydrocephalus was deﬁ ned as 
enlargement of the ventricles, without evidence of an 
obstructing lesion along the intraventricular CSF 
pathways down to the level of C1, including the fourth 
ventricular outﬂ ow tracts and the cerebral aqueduct.
The primary clinical outcome was death or severe 
disability 9 months after randomisation, assessed by 
methods described elsewhere.3 The results of a 
neurological examination were also recorded at this 
time. Secondary outcome measures included time to 
fever and coma resolution. The time to coma resolution 
was deﬁ ned as the interval (days) from randomisation to 
the time when a Glasgow coma score of 15 was reached 
and sustained for more than 2 consecutive days. Only 
patients who entered with a Glasgow coma score of less 
than 15 could enter the analysis. Fever clearance time 
was deﬁ ned as the interval from randomisation to 
observe a maximum daily temperature of less than 
37·5ºC for more than 5 consecutive days. All patients 
were febrile (temperature >37·5ºC) at randomisation. 
Neurological relapse was also documented, deﬁ ned as 
the onset of new focal neurological signs or a fall in 
Glasgow coma score of 2 points or more for 2 or more 
days, following greater than 7 days clinical stability or 
improvement at any time after randomisation. All 
deﬁ nitions were set a priori. 
Local and peripheral immune responses were assessed 
blind to clinical outcome and treatment allocation by 
methods previously described.4 Brieﬂ y, CSF cytokines 
(interferon γ, interleukin 6, interleukin 10, interleukin 
1β, tumour necrosis factor, interleukin 8, interleukin 
12p70) and chemokines (interferon-inducible protein 10 
[IP 10], monocyte-chemotactic protein 1 [MCP 1], 
regulated on activation normal T expressed and secreted 
[RANTES], and monokine induced by interferon γ [MIG]) 
were measured using a cytometric bead array assay 
(Becton Dickinson, San Diego, USA). Blood–brain barrier 
integrity was assessed by measurement of paired CSF 
and plasma albumin concentrations by standard methods 
with calculation of the albumin index using the formula 
[albumin csf ]/[albumin plasma].
Statistical analysis
The methods for primary and stratiﬁ ed subgroup 
analysis of death and disability are reported elsewhere.3 
Continuous variables were compared by the Student’s 
t test if normally distributed and the Mann-Whitney 
U test if not normally distributed. Categorical variables 
were compared by the χ² test (or Fisher’s exact test when 
appropriate). A 5% level of signiﬁ cance was used in all 
analyses. Multiple univariate comparisons using the 
tests described above were made to investigate 
associations between MRI ﬁ ndings and clinical and 
inﬂ ammatory parameters. Nine clinical variables entered 
the analysis (age, sex, disease severity grade, duration of 
symptoms, weight, Glasgow coma score, body 
temperature, and the presence of cranial nerve palsies 
and hemiplegia) and 13 CSF parameters (white-cell 
count, concentrations of neutrophils, lymphocytes, and 
total protein, CSF:blood glucose concentration, 
interferon γ, tumour necrosis factor, interleukin 6, 
interleukin 10, interleukin 8, MCP 1, RANTES, and 
albumin index). Results of this analysis were interpreted 
with caution because of the multiple comparisons and 
the increased probability of associations occurring by 
chance. Bonferroni adjustments were not used for 
reasons discussed by Perneger.6 Time to fever clearance, 
resolution of coma, and neurological relapse were 
summarised using Kaplan-Meier estimates and 
compared between patients with diﬀ erent MRI 
appearances using the log-rank test. All p values were 
two sided. All analysis was undertaken using SPSSv10 
(SPSS, Chicago, IL, USA). 
MRI (n=22) No MRI (n=28) p
BMRC grade 0·604
I 7 (32%) 7 (25%)
II 10 (46%) 11 (39%)
III 5 (23%) 10 (36%)
Cranial nerve palsy 9 (41%) 12 (43%) >0·999
Hemiplegia 4 (18%) 7 (25%) 0·734
Glasgow coma score 14 (6–15) 13 (3–15) 0·603
Glasgow coma score <11 5 (23%) 10 (36%) 0·367
Dead after 9 months of treatment 3 (14%) 9 (32%) 0·186
Data are number (%) or median (range). 
Table 2: Comparison of disease severity at start of treatment in patients with or without cerebral MRI at 
baseline
Placebo 
(n=10)
Dexamethasone 
(n=12) 
Total 
(n=22) 
Enhancement 8 (80%) 10 (83%) 18 (82%)
Basal meninges 5 (50%) 7 (58%) 12 (55%)
Sylvian ﬁ ssure 4 (40%) 9 (75%) 13 (59%)
Convexity 5 (50%) 8 (67%) 13 (59%)
Posterior fossa 0 0 0
Ventricular 1 (10%) 1 (8%) 2 (9%)
Hydrocephalus 7 (70%) 10 (83%) 17 (77%)
Communicating 6 (60%) 7 (58%) 13 (59%)
Infarction 1 (10%) 1 (8%) 2 (9%)
Tuberculoma 5 (50%) 9 (75%) 14 (64%)
Parenchymal 3 (30%) 5 (42%) 8 (36%)
Ependymal 0 3 (25%) 3 (14%)
Meningeal 2 (20%) 3 (25%) 5 (23%)
Data are number (%) or median (range).
Table 3: MRI characteristics at baseline
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Role of the funding source
The funding source had no role in study design, data 
collection, data analysis, data interpretation, or in the 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
83 scans were available for analysis from 43 patients (19 
given placebo, 24 given dexamethasone). Seven patients 
died before any scans could be taken (two given 
dexamethasone, ﬁ ve given placebo) and ﬁ ve patients died 
after one or more scans had been undertaken (three given 
placebo, two given dexamethasone). More scans were 
available from patients given dexamethasone (n=46) than 
placebo (n=37) because of the better outcome in the 
dexamethasone group. In total, 18 patients had one scan 
(two scanned at day 0, ﬁ ve scanned at day 60, and 11 
scanned at day 270 of treatment); 11 patients had two 
scans (three scanned at days 0 and 60, three scanned at 
days 0 and 270, and ﬁ ve scanned at days 60 and 270); and 
14 patients were scanned on days 0, 60, and 270. Only one 
patient was infected with HIV (all patients were tested). 
All patients received a full course of study drug started on 
the same day as the anti-tuberculosis drugs.
Table 1 shows the baseline clinical variables of the 
43 patients with one or more MRI scans for analysis. 
22 patients had a scan at the start of treatment; 28 patients 
were not able to be scanned at this time. A comparison of 
disease severity of those scanned and not scanned is 
presented in table 2 and shows that higher proportions of 
the unscanned group had more severe disease and were 
less likely to survive 9 months of treatment than the 
scanned group, although the diﬀ erences were not 
signiﬁ cant (p>0·05). 
Baseline MRI revealed that meningeal enhancement 
and hydrocephalus were common features at diagnosis, 
whereas infarction was rare (table 3). One or more 
tuberculoma were reported in nearly two-thirds of 
patients, most of which were seen within the cerebral 
parenchyma. Figure 1 shows examples of common MRI 
ﬁ ndings.
Univariate analysis was done to assess whether MRI 
ﬁ ndings on admission were associated with any of the 
nine presenting clinical features and 13 CSF inﬂ ammatory 
parameters. Hydrocephalus was associated with long 
median duration of symptoms before treatment 
(hydrocephalus 20 days, range 5–60; no hydrocephalus 
10 days, range 7–13; p=0·005). Tuberculomas were 
associated with high median bodyweight (tuberculomas 
50 kg, 45–73; no tuberculomas 45 kg, 33–60; p=0·006). 
No other signiﬁ cant associations (p<0·05) were found. 
Figure 2 shows the eﬀ ect of dexamethasone on the 
proportion of patients with enhancement, hydrocephalus, 
infarction, and tuberculoma during the 270 days of 
treatment. A signiﬁ cant number could not be scanned at 
each timepoint. Recovery was assessed at days 60 and 270 
by the modiﬁ ed Rankin disability score (mRS).3 Only one 
of 23 (4%) patients not scanned had recovered completely 
by day 60 compared with seven of 27 (26%) who were 
scanned. Furthermore, 13 of 22 (59%) not scanned were 
either dead or severely disabled at day 60 compared with 
eight of 27 (30%) who were scanned. All survivors were 
scanned at day 270, apart from four patients who did not 
attend the MRI appointment. These four patients all 
made a complete recovery (mRS=1). 
There was no signiﬁ cant reduction in the proportion of 
patients with meningeal enhancement or hydrocephalus 
at days 60 or 270 of treatment in those given dexamethasone 
compared with placebo (ﬁ gure 2). The basal meninges 
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Figure 1: Common MRI ﬁ ndings in adults with tuberculous meningitis
A: Contrast enhanced axial T1-weighted image reveals thick leptomeningeal enhancement in suprasellar cistern 
extending into sylvian ﬁ ssures and ambient cisterns. Temporal horns are also dilated. B: Contrast enhanced axial 
T1-weighted image reveals leptomeningeal enhancement within cortical sulci and sylvian ﬁ ssures. Diﬀ use low 
signal around sylvian ﬁ ssures suggests oedematous change. C: Axial T1-weighted image reveals hydrocephalus 
with dilated lateral and third ventricles. D: Sagittal T1-weighted image following intravenous contrast 
administration. There is prominent enhancement in the pituitary fossa and along the hypothalamus. The aqueduct 
of sylvius is clearly patent and third ventricle is dilated. E: Contrast enhanced coronal T1-weighted image. Multiple 
enhancing nodules, principally parenchymal but also ependymal and leptomeningeal. F: Contrast enhanced 
coronal T1-weighted image. Marked basal and right sylvian ﬁ ssure leptomeningeal enhancement is present. 
Lateral ventricles are dilated. G: Enhanced axial T1-weighted image. There is a large nodular focus of enhancement 
within the left sylvian ﬁ ssure extending into the left temporal lobe associated with substantial low-signal change. 
H: Axial T2-weighted image reveals extensive high signal within left cerebral hemisphere with large heterogeneous 
signal tuberculoma in sylvian ﬁ ssure. I: Gadolinium-enhanced T1 coronal imaging showing extensive basal 
meningeal enhancement and established left capsulostriate lacunar infarct.
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and the sylvian ﬁ ssure were the most common structures 
to enhance throughout treatment, although dexa-
methasone did not seem to aﬀ ect the site, degree, or 
duration of enhancement (data not shown). Hydrocephalus 
was identiﬁ ed in 17 of 22 (77%) patients at baseline and 18 
of 27 (67%) on day 60; the proportion with communicating 
hydrocephalus fell from 13 of 17 (77%) at baseline to ﬁ ve 
of 18 (28%) after 60 days of treatment. There was no 
signiﬁ cant diﬀ erence between the treatment groups.
The proportion of patients with one or more 
tuberculomas rose after the start of treatment from 14 of 
22 (64%) before treatment to 20 of 27 (74%) after 60 days. 
The location of the tuberculomas changed during 
treatment from predominantly aﬀ ecting the cerebral 
parenchyma before treatment (eight of 14 [57%]) to mostly 
aﬀ ecting the meninges after 60 days (19 of 20 [95%]) and 
270 days (14 of 19 [74%]) of treatment. Dexamethasone 
did not aﬀ ect the site or the total numbers of tuberculomas 
reported (data not shown) or the proportion of patients 
with one or more tuberculoma at days 60 or 270 of 
treatment (ﬁ gure 2).
Although infarction was rare at presentation (two of 22 
[9%]) it was reported in 11 of 27 (41%) after 60 days of 
treatment. A smaller proportion occurred in those treated 
with dexamethasone (27%) than in those treated with 
placebo (58%, p=0·13; ﬁ gure 2). Infarction predominantly 
involved the basal ganglia and the internal capsule. All of 
the infarcts reported on day 0 (two of two) and at day 60 
(11 of 11) involved the basal ganglia; three of 11 patients 
also had internal capsule infarction at day 60 of treatment. 
Infarcts of the corpus callosum (n=1) and the cerebral 
cortex supplied by the middle cerebral artery (n=1) were 
also reported. Dexamethasone did not seem to aﬀ ect the 
location of the infarcts (data not shown).
After 60 days of treatment, associations were sought 
between enhancement, hydrocephalus, infarction, and 
tuberculomas seen on MRI and nine clinical features 
and 13 CSF inﬂ ammatory parameters. Signiﬁ cant 
associations (p<0·05) are presented in tables 4–6. 
Hydrocephalus was associated with a persistent 
inﬂ ammatory response with raised CSF concentrations 
of protein, interferon γ, interleukin 10, and interleukin 
6. The presence of tuberculomas was also associated 
with increased numbers of white cells in the CSF, a 
higher proportion of which were neutrophils, and 
increased concentrations of protein, interleukin 6, and 
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Figure 2: Eﬀ ect of dexamethasone on MRI appearances of tuberculous meningitis during treatment
Proportions of patients with post-contrast enhancement (A), cerebral infarcts (B), tuberculomas (C), and hydrocephalus (D) before and after treatment with 
dexamethasone (blue bars) or placebo (red bars).
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interleukin 10. Infarction was associated with reduced 
CSF:plasma glucose ratio, increased concentrations of 
interleukins 8 and 10 in CSF, and greater impairment of 
blood–brain barrier dysfunction (as assessed by albumin 
index). No signiﬁ cant associations were shown between 
contrast enhancement on MRI and any of the clinical or 
CSF parameters.
Multivariate analysis of variables independently 
associated with MRI appearances at baseline and after 
60 days of treatment was attempted, but was impossible 
because the number of observations was fewer than the 
number of parameters in the model.
MRI appearances at diagnosis or after 60 days of 
treatment were not associated (p>0·05) with death or 
disability after 9 months of treatment (data not shown). 
34 patients were scanned and examined at the end of 
treatment. 14 recovered without any neurological 
sequelae, although MRI revealed meningeal enhancement 
in one, hydrocephalus in three, infarction in ﬁ ve, and 
tuberculoma in seven. 16 patients were left with some 
neurological symptoms but could live independently; 
their MRI revealed enhancement in seven, hydrocephalus 
in 13, infarction in eight, and tuberculoma in nine. Four 
patients were severely disabled at the end of treatment 
and MRI showed enhancement in two, hydrocephalus in 
three, infarcts in three, and tuberculoma in three. 
Although there were no signiﬁ cant associations with 
fever clearance or coma resolution and MRI ﬁ ndings at 
diagnosis, median fever clearance times were signiﬁ cantly 
longer in those with tuberculoma seen on MRI at day 60 
of treatment (median time 6 vs 12 days, p=0·018) than in 
those without tuberculoma. Only hydrocephalus seen on 
day 60 was clearly associated with prolonged coma 
resolution (median 16 vs 4 days, p=0·004). Tuberculomas 
seen at day 60 had no signiﬁ cant eﬀ ect on coma resolution 
times. Seven patients relapsed neurologically during 
treatment, but there were no signiﬁ cant associations 
between MRI ﬁ ndings at baseline or 60 days and relapse 
(data not shown).
Discussion
The results provide important clinical data for use of MRI 
to assess treatment responses in tuberculous meningitis 
and important pathophysiological data for how 
dexamethasone might act to improve outcome from 
tuberculous meningitis by reducing hydrocephalus and 
preventing infarction
There are some important limitations to the study. In 
particular, there were a large number of missing scans, 
predominantly from patients with more severe disease. 
As a result, comparisons of the MRI ﬁ ndings between 
the two treatment groups were not based on the same 
group of patients at each timepoint. This scenario is 
especially problematic when comparing data across 
timepoints. Additionally, more patients in the placebo 
group than in the dexamethasone group did not complete 
the study because of death. Consequently, the eﬀ ect of 
dexamethasone on the major complications of 
tuberculous meningitis (infarction and hydrocephalus) 
might have been under-estimated as only survivors with 
less severe disease tended to be scanned.
The MRI appearances described at baseline of patients 
in this study are similar to those reported in previous 
studies.7 Hydrocephalus and basal meningeal 
enhancement were the most common presenting 
ﬁ ndings, with hydrocephalus occurring most often in 
those with a long duration of symptoms. Hydrocephalus 
seen after 60 days of treatment was associated with long-
term coma and a protracted inﬂ ammatory response 
within the CSF, although conclusions from this analysis 
must be interpreted with caution in view of the multiple 
comparisons undertaken. 
The role of dexamethasone in treating hydrocephalus 
is uncertain. Analysis from all patients recruited to the 
trial showed that dexamethasone was associated with 
faster defervescence but not with reduced coma resolution 
times3 and this study did not show dexamethasone to 
signiﬁ cantly reduce hydrocephalus at days 60 and 270 of 
treatment. Many authorities advocate ventricular–
peritoneal shunts for the treatment of hydrocephalus 
associated with tuberculous meningitis, especially in 
Hydrocephalus  (n=18) No hydrocephalus (n=9) p
Protein (mg/L) 2100 (360–5500); [n=17] 800 (270–2470) 0·009
Interferon γ (pg/mL) 312·1 (14·6–12074·2); [n=16] 38·4 (0·1–163·5); [n=8] 0·002
Interleukin 10 (pg/mL) 30·3 (14·6–133·7) [n=16] 9·2 (0·1–14·4) [n=8] 0·006
Interleukin 6 (pg/mL) 408·9 (35·9–1429·0); [n=16] 89·6 (9·9–340·1); [n=8] 0·004
Number and denominator given only when there are missing values.
Table 4: CSF variables signiﬁ cantly (p<0·05) associated with hydrocephalus on MRI after 60 days of 
treatment 
Tuberculoma (n=20) No tuberculoma (n=7) p
Total white cell count (×106/mL) 120 (24–600) 30 (4–180) 0·040
Percent neutrophils/lymphocytes 10 (2–39) / 90 (61–98) 2 (0–20) / 98 (80–100) 0·025
Protein (mg/L) 1980 (600–5500) 700 (270–2260) 0·030
Interleukin 10 (pg/mL) 27·9 (0·1–133·7); [n=16] 7·6 (0·1–21·9); [n=6] 0·042
Interleukin 6 (pg/mL) 325·7 (14·3–1429·0); [n=18] 89·6 (9·9–490·9); [n=6] 0·004
Number and denominator given only when there are missing values.
Table 5: CSF variables signiﬁ cantly (p<0·05) associated with tuberculoma on MRI after 60 days of 
treatment 
Infarction (n=11) No infarction (n=16) p
CSF:plasma glucose 0·37 (0·28–0·52) 0·43 (0·32–0·84) 0·038
Interleukin 10 (pg/mL) 46·2 (6·64–133·7); [n=8] 14·2 (0·1–36·6); [n=12] 0·040
Interleukin 8 (pg/mL) 1219·5 (187·3–2280·5); [n=8] 312·8 (36·9–1589·9); [n=12] 0·026
Albumin index 2·70 (1·10–11·02); [n=7] 0·62 (0·04–2·43); [n=11] 0·004
Number and denominator given only when there are missing values.
Table 6: CSF variables signiﬁ cantly (p<0·05) associated with infarction on MRI after 60 days of treatment 
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those with non-communicating hydrocephalus or in 
those with persistent coma.8 Neurosurgical intervention 
was not available to our patients, which aﬀ ects the 
generalisability of the controlled trial results. However, 
these MRI data do not suggest dexamethasone’s eﬀ ect on 
survival occurs primarily by treating and preventing 
hydrocephalus. Indeed, the increased proportion of 
patients with non-communicating hydrocephalus 
between baseline and 60 days of treatment (28% to 72%) 
suggests that ventricular–peritoneal shunting should be 
considered in all those with hydrocephalus who do not 
respond to medical treatment. 
Tuberculomas have been considered a well-described 
but relatively rare complication of tuberculous meningitis. 
Indeed, their occurrence has been the subject of several 
case reports, often under the headline of paradoxical 
treatment reactions.9 Therefore, to ﬁ nd 74% of patients 
had tuberculomas evident on MRI after 60 days of 
treatment was surprising. To the best of our knowledge 
this is the ﬁ rst published prospective study to report 
serial MRI in a cohort of patients with tuberculous 
meningitis. Previous MRI studies have only scanned 
selected symptomatic patients (deteriorating on 
treatment, for example). Our data suggest tuberculomas 
form in most patients during treatment, predominantly 
within the meninges, and could be a typical rather than a 
paradoxical aspect of disease resolution. Their presence 
was associated with a prolonged fever clearance time and 
inﬂ ammation in the CSF, but in most patients they seem 
to be asymptomatic. Indeed, half of those who made a 
complete recovery after 270 days of treatment had 
tuberculomas seen on MRI. Dexamethasone seemed to 
have no eﬀ ect on their incidence or resolution. Whether 
tuberculomas cause clinical problems is probably 
dependent on their size and anatomical location, but 
further research is needed to address these issues and 
the role of corticosteroids in their management.
Cerebral infarction is an important complication of 
tuberculous meningitis and this study, like others, 
conﬁ rms that the perforating vessels to the basal ganglia 
are most commonly occluded.10 Most infarcts seemed to 
occur after starting treatment, although the proportion 
with infarction at this time was probably an under-
estimate because the more seriously ill at baseline could 
not be scanned. However, after 60 days of treatment more 
than double the proportion of patients had had an infarct 
in the placebo group compared with in the dexamethasone 
group (p=0·130) . 
In summary, hydrocephalus was the most common 
serious complication of tuberculous meningitis and was 
strongly associated with long-term coma. Tuberculomas 
developed in most patients during treatment, which 
suggests that they are part of the normal pathological 
response to treated infection. Infarctions were often 
multiple and always aﬀ ected the basal ganglia. The eﬀ ect 
of dexamethasone on these complications is unclear in 
view of the numbers of missing scans, although the 
proportions of patients with hydrocephalus and 
infarctions in the dexamethasone group could have been 
even smaller had the most severe patients from the 
placebo group been scanned. Therefore, dexamethasone 
might improve survival from tuberculous meningitis by 
reducing the incidence of infarction and speeding the 
resolution of hydrocephalus, but the anti-inﬂ ammatory 
mechanisms for doing so remain obscure. Other 
extracerebral eﬀ ects of dexamethasone might be equally 
important. In particular, dexamethasone might protect 
against severe drug-related liver toxicity and prevent 
life-threatening interruptions in anti-tuberculosis 
chemotherapy.3
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